Diminishing Returns from the Government’s Drug Negotiation Program
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the next 15 drugs that will be subject to government price negotiations.
Would Senate Passage of an ACA Tax Credit Extension Matter?
Last week, under a rarely used procedure known as a discharge motion, the House of Representatives passed a three-year extension of the enhanced Affordable Care Act (ACA) healthcare tax credit, which expired on December 31.
MGA Brief Examines State and Federal PBM Mandates
Congress considered but ultimately declined to enact legislation mandating that pharmacy benefit managers (PBMs) operate in a prescribed financial arrangement with their customers.
FDA Moves to Facilitate Biosimilar Development
Yesterday, the Food and Drug Administration (FDA) announced long-overdue reforms to the biosimilar approval process that will boost biosimilar development and competition in the United States.
How Pharmaceutical Tariffs Will Affect US Health Care Costs
Tariffs on pharmaceuticals are under consideration following a Section 232 investigation into imports of medicines and active pharmaceutical ingredients (APIs).
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
- The 340B Program’s Negative Impact on Pharmaceutical Innovation
